News
Video
Reflecting on Recent Updates, Changing Landscape of IgAN, with Jonathan Barratt, MD, PHD
Author(s):
Key Takeaways
- IgA nephropathy management is evolving with new pharmacotherapies, improving patient prognosis significantly.
- Nephrology is now witnessing rapid advancements, including small molecules, biologics, and gene therapy.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.
The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of the several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline. Now, with multiple fully approved therapies, the prognosis for patients is brighter than at any point in history.
In this video, which is the first in a 5-part series, Barratt reflects on the evolving field of nephrology and expresses excitement for the influx of new treatments that have transformed the specialty. For much of his career, nephrology lacked innovation compared to fields like oncology and rheumatology, resulting in limited treatment options and less interest from prospective clinicians.
However, Barratt highlights that nephrology is now witnessing rapid advancements, including small molecules, biologics, antisense oligonucleotides, and even gene therapy. As new therapies offer meaningful improvements in patient outcomes, he encourages younger clinicians to consider nephrology, emphasizing the field’s newfound potential to make a significant impact on patients' lives.
Relevant disclosures of interest for Barratt included Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, and Travere Therapeutics.
